Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention

European Heart Journal

Volumn 31, Issue 5, 2010, Pages 561-572

  Rassen, Jeremy A ^a,b   Mittleman, Murray A ^b,c   Glynn, Robert J ^a,b   Alan Brookhart, M ^a   Schneeweiss, Sebastian ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Anti thrombotic treatments; Confounding factor (epidemiology); Instrumental variable analysis; Percutaneous coronary intervention; Pharmacoepidemiology

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK FACTOR;

ACUTE CORONARY SYNDROME; ANGIOPLASTY; ANTITHROMBINS; COHORT STUDIES; FEMALE; HIRUDINS; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; UNITED STATES;

EID: 77749254796     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp437     Document Type: Article

References (53)

1. Label for bivalirudin. http://dailymed.nlm.nih.gov/dailymed/getFile.cfm? id=12006& type=pdf&name=911cd48f-01ea-4dec-b30c-95e7e0ea9d2a (10 November 2009).
2. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revasculari-zation: REPLACE-2 randomized trial. JAMA 2004;292:696-703.
3. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863.
4. Antman EM. Should bivalirudin replace heparin during percutaneous coronary interventions? JAMA 2003;289:903-905.
5. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI. Antithrombo-tic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl. 3): 576S-599S.
6. Kwa AT, Rogers JH. Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy. J Interv Cardiol 2008;21:107-117.
7. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-2216.
8. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-2230.
9. Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, Khattab AA, Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, Schomig A. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008;359: 688-696.
10. Schneeweiss S, Seeger JD, Landon J, Walker AM. Use of aprotinin or aminoca-proic acid during CABG surgery and risk of death. N Engl J Med 2008;358: 771-783.
11. Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perio-perative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2005;353:349-361.
12. CMS-1450/UB-92 Form. http://cms.hhs.gov/providers/edi/h1450.pdf (9 June 2008).
13. Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004;291:2092-2099.
14. United States, Health Care Financing Administration. The International Classification of Diseases, 9th Revision, Clinical Modification: ICD-9-CM. 3rd ed. Washington, DC: US Department of Health and Human Services, Public Health Service; 1989.
15. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/ SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006;47:e1-e121.
16. Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC, Mehran R, Pocock SJ. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 2007;298:2497-2506.
17. Cox DR. Regression models and life tables. J R Stat Soc, Series B 1972;20:187-220.
18. Huber PJ. The behavior of maximum likelihood estimates under non-standard conditions. In: Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. Berkeley, CA: University of California Press; 1967. p221-233.
19. Hellevik O. Linear versus logistic regression when the dependent variable is a dichotomy. Qual Quant 2007. Published online ahead of print 16 February 2007.
20. Cheung YB. A modified least-squares regression approach to the estimation of risk difference. Am J Epidemiol 2007;166:1337-1344.
21. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York: Wiley; 2000.
22. Singh M, Lennon RJ, Holmes DR Jr, Bell MR, Rihal CS. Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention. J Am Coll Cardiol 2002;40:387-393.
23. Rassen JA, Brookhart MA, Mittleman MA, Glynn RJ, Schneeweiss S. Instrumental variables 1: exploiting quasi-random treatment choice to construe causal relationships. J Clin Epidemiol 2009. Published online ahead of print.
24. Greene WH. Econometric Analysis. 5th ed. Upper Saddle River, NJ: Prentice Hall; 2003.
25. Hernán MA, Robins JM. Instruments for causal inference: an epidemiologist's dream? Epidemiology 2006;17:360-372.
26. Angrist JD, Imbens G, Rubin DB. Identifcation of causal effects using instrumental variables. J Am Stat Assoc 1996;94:444-455. (Pubitemid 126412813)
27. McClellan M, McNeil BJ, Newhouse JP. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables. JAMA 1994;272:859-866.
28. Brookhart MA, Schneeweiss S. Preference-based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results. Int J Biostat 2007;3:article 14.
29. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 2006;17:268-275.
30. Brennan TA, Hebert LE, Laird NM, Lawthers A, Thorpe KE, Leape LL, Localio AR, Lipsitz SR, Newhouse JP, Weiler PC, Hiatt HH. Hospital characteristics associated with adverse events and substandard care. JAMA 1991;265:3265-3269.
31. Ayanian JZ, Weissman JS. Teaching hospitals and quality of care: a review of the literature. Milbank Q 2002;80:569-593, v.
32. Kupersmith J. Quality of care in teaching hospitals: a literature review. Acad Med 2005;80:458-466.
33. Rassen JA, Schneeweiss S, Glynn RJ, Mittleman MA, Brookhart MA. Instrumental variable analysis for estimation of treatment effects with dichotomous outcomes. Am J Epidemiol 2009;169:273-284.
34. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York: Chapman & Hall; 1993.
35. Bound J, Jaeger DA, Baker RM. Problems with instrumental variables estimation when the correlation between the instruments and the endogenous explanatory variable is weak. J Am Stat Assoc 1995;90:443-450.
36. Staiger D, Stock JH. Instrumental variable regression with weak instruments. Econ-ometrica 1997;65:557-586.
37. Stock JH, Yogo M. Testing for weak instruments in linear IV regression. In Andrews DWK, Stock JH (eds). Identification and Inference for Econometric Models: Essays in Honor of Thomas Rothenberg. Cambridge and New York: Cambridge University Press; 2005. p80-108.
38. Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S. Instrumental variables 2: in 25 variations, the physician prescribing preference generally was strong and reduced imbalance. J Clin Epidemiol 2009; published online ahead of print.
39. Mahalanobis PC. On the generalized distance in statistics. Proc Natl Inst Sci India 1936;12:49-55.
40. Baum CF, Schaffer ME, Stillman S. ivreg2: Stata module for extended instrumental variables/2SLS and GMM estimation. Statistical Software Components. Boston, MA: Boston College Department of Economics; 2006.
41. Rothman KJ. Modern Epidemiology. Philadelphia: Lippincott Williams & Wilkins; 1998.
42. Hausman J. Specification tests in econometrics. Econometrica 1978;46:1251-1271.
43. Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology 2005;16:17-24.
44. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf 2005;14:465-476.
45. Sturmer T, Schneeweiss S, Avorn J, Glynn RJ. Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol 2005;162:279-289.
46. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22.
47. Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health 1998;19:17-34.
48. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA. Risk of death in elderly users of conventional vs. atypical antipsy-chotic medications. N Engl J Med 2005;353:2335-2341.
49. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 2007;297:278-285.
50. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005;58:323-337.
51. Wooldridge JM. Introductory Econometrics: A Modern Approach. 3rd ed. Mason, OH: Thomson/South-Western; 2006.
52. Schneeweiss S, Glynn RJ, Avorn J, Solomon DH. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol 2005;58:98-102.
53. Solomon DH, Schneeweiss S, Glynn RJ, Levin R, Avorn J. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med 2003;115:715-720.